Clinical Trial Update: Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif [Phase 4]

View source ↗

Summary

Phase 4 safety study in relapsing-remitting multiple sclerosis patients treated with Betaferon or Rebif; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Betaferon (interferon beta-1b)
• Rebif (interferon beta-1a)

Snippet

Sponsor: Bayer | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2013-10-21